Core Viewpoint - Zhang Jian Sheng's investment philosophy emphasizes a low-risk approach, focusing on absolute returns rather than high-risk growth stocks, which has led to impressive performance metrics, including a 45.97% return in 2025 and a 65.38% return over the past three years [1]. Group 1: Investment Characteristics - The investment strategy is characterized by a top-down approach with a concentrated selection of stocks, typically holding 1-2 stocks per industry, resulting in low turnover rates [2]. - The portfolio is industry-balanced, primarily focusing on high-end manufacturing, TMT (Technology, Media, and Telecommunications), and consumer sectors, without betting on specific sub-sectors [3]. - A moderately contrarian style is adopted, with an emphasis on valuation and avoiding pure beta returns, leading to early buying and selling of growth stocks compared to peers [3][11]. Group 2: Sector Insights - In the AI industry chain, there is a preference for storage and connectivity segments, with increased focus on AI application investments starting in 2026 [3][20]. - The consumer sector faces challenges with insufficient overall consumption, leading to investments in companies adapting to changes in consumption channels [4]. - In the Hong Kong innovative drug sector, the phase of valuation recovery has ended, with current investments concentrated in companies with overseas commercialization channels [5][23]. - The overall valuation in the metals sector, excluding gold, remains low, and the anticipated interest rate cuts in the US are favorable for commodities [6]. Group 3: Market Outlook - The outlook for the bull market is optimistic, with the belief that it is entering its second half, necessitating a more stable mindset and a balanced portfolio approach [6][19]. - The investment opportunities for 2026 are expected to diversify beyond non-linear growth sectors like AI and resources, with a focus on cyclical industries experiencing valuation recovery [19]. - The "re-globalization" narrative is seen as beneficial for Chinese companies, enhancing their performance and long-term growth potential, which may lead to a revaluation of core Chinese assets, including those in the Hong Kong market [18][19]. Group 4: Investment Strategy Adjustments - The investment approach will involve a slower trading pace, with a more cautious evaluation of opportunity costs, while maintaining a left-side investment framework [28]. - Emphasis will be placed on large-cap stocks due to the increasing influence of passive and quantitative funds in the market [29]. - The strategy will focus on companies with price elasticity and those that can create demand through supply, which may become advantageous in the current bull market environment [29].

Core Viewpoint - The article emphasizes the transformative opportunities in the innovative pharmaceutical sector, predicting that 2025 will mark a significant year for revenue growth, profit breakthroughs, and valuation increases in the industry [4][5]. Group 1: Innovative Drug Investment Outlook - The innovative drug sector is entering a "three-dimensional screening era" characterized by major disease categories, clinical data validation, and global competition [4]. - 2025 is anticipated to be the starting point for collective revenue growth among innovative drug companies, with 80% of A-share and Hong Kong-listed innovative drug firms expected to see revenue increases following 2024's medical insurance negotiations [5]. - The period from 2025 to 2028 is projected to be crucial for many Chinese innovative drug companies to enter profitability, contrasting with previous years where only a few companies achieved profits [5]. Group 2: Key Investment Areas in Innovative Drugs - Focus areas for investment include: 1. Bispecific antibodies, with the first approved product in China and several in late-stage clinical trials [8]. 2. Antibody-drug conjugates (ADCs), where domestic companies lead in the development of the next generation of ADCs [8]. 3. Targeted therapies, with the global oncology drug market exceeding $150 billion, and a significant share expected to come from domestic small molecules by 2030 [8]. 4. Autoimmune diseases, driven by environmental factors and improved insurance coverage, with a focus on kidney disease drugs showing substantial growth [8]. Group 3: Investment Strategy and Methodology - The investment strategy in the pharmaceutical sector is based on three selection criteria: 1. Focus on large market spaces, such as oncology and metabolic diseases, to mitigate R&D risks [10]. 2. Prefer clear competitive landscapes, such as orphan drugs, with minimal competition expected in the next three years [10]. 3. Target products with optimal clinical data, avoiding those that do not meet top-tier standards [10]. Group 4: Insights from Fund Managers - Fund manager Wu Qingyu emphasizes the importance of absolute return thinking, focusing on high-growth sectors while maintaining valuation discipline [11][12]. - Wu's investment approach combines top-down and bottom-up strategies, selecting high-growth industries and then identifying companies with superior growth rates and matching valuations [15]. - The focus on concentrated holdings is driven by strong research conclusions, aiming for higher alpha returns through precise stock selection [17]. Group 5: Future Investment Directions - Wu Qingyu identifies three key sectors for future investment: 1. AI computing power, driven by increased domestic demand for servers and capital investments from companies like ByteDance [19]. 2. Investment opportunities in "AI new hardware" arising from the integration of AI models with downstream hardware [19]. 3. The automotive sector's trend towards smart technology, with certain domestic manufacturers expected to gain market share [19].

Core Viewpoint - The article highlights the successful investment strategies of fund manager Wu Qingyu, who has achieved significant returns through a focus on absolute returns and a GARP (Growth at a Reasonable Price) investment philosophy [1][2][3]. Group 1: Investment Philosophy - Wu Qingyu emphasizes the importance of absolute return thinking, which combines selecting high-quality assets at reasonable prices to achieve long-term gains [2][3]. - The GARP strategy aligns with Wu's investment approach, focusing on balancing valuation and growth to ensure investments are made at low or reasonable valuations [2][3]. Group 2: Market Strategy - Wu adopts a long-term perspective, prioritizing the intrinsic value of companies over short-term market fluctuations, and is willing to endure temporary volatility for potential long-term gains [3][4]. - He identifies structural opportunities in various industries by analyzing supply-demand mismatches, particularly in sectors like AI, manufacturing, and renewable energy [4][7]. Group 3: Stock Selection and Portfolio Management - Wu employs a combination of top-down and bottom-up approaches in stock selection, focusing on high-growth sectors while adhering to GARP principles [4][5]. - He maintains a concentrated portfolio, believing that strong research backing is essential for high-conviction investments, which can lead to superior returns [6]. Group 4: Future Outlook - Wu is optimistic about the equity market, anticipating a bullish trend supported by global liquidity and domestic economic policies [7]. - He is particularly focused on three key sectors: AI computing, new hardware related to AI, and the automotive industry's shift towards smart technologies [7].